EP
RCUS icon

Essential Partners’s Arcus Biosciences RCUS Stock Holding History

Essential Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$646 Hold
25
– – ﹤0.01% 2322
2026
Q2 		$771 Hold
25
– – ﹤0.01% 2348
2026
Q1 		$540 Hold
25
– – ﹤0.01% 2413
2025
Q4 		$596 Hold
25
– – ﹤0.01% 2186
2025
Q3 		$340 Hold
25
– – ﹤0.01% 2288
2025
Q2 		$204 Buy
+25
New +$214 ﹤0.01% 1938

Other funds holding RCUS

Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

Essential Partners's RCUS Position: Q3 2026 in Review

Essential Partners held its Arcus Biosciences (RCUS) position steady in Q3 2026 at 25 shares worth $646. The position accounts for ﹤0.01% of the portfolio, ranked #2322.

Essential Partners first reported a position in RCUS in Q2 2025 and has held it in 6 quarters since. The position peaked at $771 in Q2 2026. 16 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • Essential Partners held 25 shares of Arcus Biosciences worth $646 as of Q3 2026.
  • Essential Partners left its Arcus Biosciences share count unchanged in Q3 2026.
  • Arcus Biosciences made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2322 holding.
  • Essential Partners first reported a position in Arcus Biosciences in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Arcus Biosciences position peaked at $771 in Q2 2026.
  • 16 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.